Alexion to Acquire Wilson Therapeutics: Click Here For Transaction Details and Disclosures
Share, Send, or Save

Soliris®  (eculizumab)

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris®  works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a role in serious diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).1

Soliris®  has earned some of the pharmaceutical industry’s highest honors for innovation, including the 2008 Prix Galien USA Award for Best Biotechnology Product and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases.

Learn more about Soliris®  for the treatment of adult patients with PNH

soliris®  and pnh

Learn more about Soliris®  for the treatment of patients with aHUS

soliris®  and aHUS

Learn more about Soliris®  for the treatment of adult patients with gMG

soliris®  and gMG

More Information



Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris®. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris®, unless the risks of delaying Soliris®  therapy outweigh the risk of developing a meningococcal infection.
  • Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Soliris®  is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris®  REMS, prescribers must enroll in the program. Enrollment in the Soliris®  REMS program and additional information are available by telephone: 1-888-SOLIRIS® (1-888-765-4747) or at 

Indications and Usage

Paroxysmal Nocturnal Hemoglobinuria (PNH)
Soliris®  is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Atypical Hemolytic Uremic Syndrome (aHUS)
Soliris®  is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use
Soliris®  is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Generalized Myasthenia Gravis (gMG)
Soliris®  is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.


Soliris®  is contraindicated in:

  • Patients with unresolved serious Neisseria meningitidis infection
  • Patients who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying Soliris®  treatment outweigh the risks of developing a meningococcal infection

Warnings and Precautions

Other Infections
Soliris®  blocks terminal complement activation; therefore patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with Soliris®  may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenza type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenza type b (Hib) infections according to ACIP guidelines. Use caution when administering Soliris®  to patients with any systemic infection.

Monitoring Disease Manifestations After Soliris®  Discontinuation
Treatment Discontinuation for PNH
Monitor patients after discontinuing Soliris®  for at least 8 weeks to detect hemolysis.

Treatment Discontinuation for aHUS
After discontinuing Soliris®, monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. In aHUS clinical trials, 18 patients (5 in the prospective studies) discontinued Soliris®  treatment. TMA complications occurred following a missed dose in 5 patients, and Soliris®  was reinitiated in 4 of these 5 patients.

Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis. In addition, the following changes in laboratory parameters may identify a TMA complication: occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during Soliris®  treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during Soliris®  treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during Soliris®  treatment.

If TMA complications occur after Soliris®  discontinuation, consider reinstitution of Soliris®  treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures.

Thrombosis Prevention and Management
The effect of withdrawal of anticoagulant therapy during Soliris®  treatment has not been established. Therefore, treatment with Soliris®  should not alter anticoagulant management.

Infusion Reactions
Administration of Soliris®  may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion reaction which required discontinuation of Soliris®. Interrupt Soliris®  infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

Adverse Reactions

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea.

The most frequently reported adverse reactions in aHUS single arm prospective trials (≥20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia.

The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥10%) is: musculoskeletal pain.

Please see full prescribing information for Soliris®, including boxed WARNING regarding serious meningococcal infection.


  1. Soliris®  [package insert]. Alexion Pharmaceuticals Inc; revised 1/2017.